
Bo Zhong
Articles
-
Nov 19, 2024 |
mdpi.com | Junjun Wu |Yi Li |Bo Zhong |Yan Zhang
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Mar 9, 2023 |
nature.com | Bo Zhong
Immune checkpoint inhibitors (ICIs), represented by anti-PD-1/PD-L1 antibodies, have been widely applied in various cancers, and the efficacy of ICIs is closely associated with the tumor immune microenvironment (TIME) [1, 2].
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →